Tuesday, January 30, 2018 8:13:50 AM
That was just the most recent hit from the NNVC "play list":
"My guess - we see Phase I Clinical trials for the anti-Shingles drug begin in Australia no earlier than April-May, and possibly not until Summer. If the Phase I goes smoothly, they should be able to get Phase II rolling during the Summer or Early Fall - assuming that they plan to do that in Australia as well and have their clinical 'ducks' all in a row. "
"I want to see 'something' go into TOX testing by sometime this Summer. My confidence will remain high until at least then,... afterwards I'll be wanting a few questions answered by the company as to what might be causing a delay. "
"I think a lot of pieces are moving - just out of sight of us and of the market. It would not shock me in the least to have some very positive bits of news start to come out over the next few weeks. In fact - I am starting to feel anticipatory for the first time this year."
"I would view that as a definite bit of positive news - if we were to get it before [insert date] starts."
"I'm guessing that we'll be hearing some news about the tox work being done soon, and hopefully that will let us hold back up over $1 for a while."
"My guess - we see Phase I Clinical trials for the anti-Shingles drug begin in Australia no earlier than April-May, and possibly not until Summer. If the Phase I goes smoothly, they should be able to get Phase II rolling during the Summer or Early Fall - assuming that they plan to do that in Australia as well and have their clinical 'ducks' all in a row. "
"I want to see 'something' go into TOX testing by sometime this Summer. My confidence will remain high until at least then,... afterwards I'll be wanting a few questions answered by the company as to what might be causing a delay. "
"I think a lot of pieces are moving - just out of sight of us and of the market. It would not shock me in the least to have some very positive bits of news start to come out over the next few weeks. In fact - I am starting to feel anticipatory for the first time this year."
"I would view that as a definite bit of positive news - if we were to get it before [insert date] starts."
"I'm guessing that we'll be hearing some news about the tox work being done soon, and hopefully that will let us hold back up over $1 for a while."
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
